SaluTech has developed a proprietary conductive biomaterial (CBM) to treat patients suffering from Atrial Fibrillation (AF), addressing the underlying electrophysiological cause of AF to restore a normal heartbeat. CBM is uniquely able to mimic the conductive velocity of healthy heart tissue and can resynchronize erratic electrical signals characteristic of AF. We have strong preclinical research data in small and large animals supporting its safety and efficacy, with plans to meet with USFDA later this year.

SaluTech logo



Event details

Date: September 14 - 16, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


16 in total